Karolinska Institute Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (33)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Karolinska Institute - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Karolinska Institute. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There is 1 cancer drugs by Karolinska Institute which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Karolinska Institute - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Karolinska Institute - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Karolinska Institute. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There is 1 cancer drugs by Karolinska Institute which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Karolinska Institute - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Karolinska Institute

  1.1 Business Overview

  1.2 Karolinska Institute Cancer Pipeline Overview

 

2. Karolinska Institute Cancer Drugs in Research Phase

  2.1 Cancer Therapeutics - Sprint Bioscience/Karolinska Institute

  2.2 Natural killer Cell Based Therapies - Sorrento/Karolinska Institutet

 

3. Karolinska Institute Cancer Drugs in Preclinical Phase

  3.1 Immunotherapeutic Vaccines – Scancell

  3.2 KAN 0438757

  3.3 Anti-Angiomotin Antibodies – BioInvent

 

4. Karolinska Institute Cancer Drugs in Phase-I

  4.1 VLX 600

  4.2 VLX 1570

 

5. Karolinska Institute Cancer Drugs in Phase-I/II

  5.1 Colorectal Cancer DNA Vaccine - Cellectis/Karolinska Institute

 

6. Karolinska Institute Cancer Drugs in Phase-II

  6.1 Busulfan Liposomal

 

7. Marketed Cancer Drugs by Karolinska Institute

  7.1 Palbociclib

 

8. No Development Reported In Cancer Drugs in Clinical Pipeline

  8.1 Natural killer Cell Therapy – Avaris

  8.2 Histone Deacetylase Inhibitors - S*BIO/Karolinska Institute

 

9. Discontinued in Cancer Drugs in Clinical Pipeline

  9.1 Prostate Cancer DNA Vaccine - Cellectis/Karolinska Institute

  9.2 Zidovudine Stem Cell Therapeutics - ZGene/Karolinska Institute

  9.3 PRIMA-1


Figure 1-1: Karolinska Institute Cancer Pipeline by Phase (%)

Figure 1-2: Karolinska Institute Cancer Pipeline by Phase (Number)

Figure 1-3: Karolinska Institute Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Karolinska Institute Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)